Plus Therapeutics, Inc. (PSTV)

NASDAQ: PSTV · IEX Real-Time Price · USD
1.720
-0.010 (-0.58%)
Jul 19, 2024, 9:57 AM EDT - Market open
-0.58%
Market Cap 9.98M
Revenue (ttm) 6.08M
Net Income (ttm) -11.77M
Shares Out 5.70M
EPS (ttm) -3.04
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 2,253
Open 1.720
Previous Close 1.730
Day's Range 1.720 - 1.775
52-Week Range 0.970 - 3.210
Beta 0.54
Analysts Strong Buy
Price Target 8.00 (+365.12%)
Earnings Date Aug 12, 2024

About PSTV

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. The company also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere that is designed to treat various solid organ ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1996
Employees 20
Stock Exchange NASDAQ
Ticker Symbol PSTV
Full Company Profile

Financial Performance

In 2023, PSTV's revenue was $4.91 million, an increase of 2093.30% compared to the previous year's $224,000. Losses were -$13.32 million, -34.32% less than in 2022.

Financial Statements

Analyst Forecast

According to one analyst, the rating for PSTV stock is "Strong Buy" and the 12-month stock price forecast is $8.0.

Price Target
$8.0
(365.12% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Plus Therapeutics to Present at the Gordon Research Conference Radionuclide Theranostics for the Management of Cancer

AUSTIN, Texas, July 02, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with ad...

17 days ago - GlobeNewsWire

Plus Therapeutics Expands Management Team and Reports $3.3M Advance Payment from CPRIT

Greg Fuller, M.D., Ph.D., former Professor of Pathology (Neuro-Pathology) & Neuro-Radiology at The University of Texas MD Anderson Cancer Center joins Plus as Vice President of Medical Affairs and Med...

6 weeks ago - GlobeNewsWire

Plus Therapeutics Announces New Employment Inducement Grants

AUSTIN, Texas, May 17, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq:  PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced pl...

2 months ago - GlobeNewsWire

Plus Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

Announced private placement of up to $19.25M with healthcare funds and insiders Received $3M award recommendation from the Department of Defense to support Plus' clinical brain cancer program Acquired...

2 months ago - GlobeNewsWire

Plus Therapeutics to Announce First Quarter Financial Results and Host Conference Call on May 15, 2024

AUSTIN, Texas, May 13, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq:  PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced pl...

2 months ago - GlobeNewsWire

Plus Therapeutics Provides Highlights Regarding Leptomeningeal Metastases Acquisition and Topline Clinical Trial Data on the FORESEE Trial

Company acquired assets for the synergistic leptomeningeal metastases (LM) diagnostic platform, “CNSide™ ” and discussed potential partnering opportunities CNSide can significantly improve LM diagnost...

2 months ago - GlobeNewsWire

Plus Therapeutics to Host Investor Call to Discuss Leptomeningeal Cancer Related Acquisition and Topline Clinical Trial Data from the FORESEE Trial

Company acquired all assets for the synergistic CNSide cerebrospinal fluid diagnostic portfolio Company will summarize topline data from the FORESEE clinical trial planned for presentation at the SNO/...

2 months ago - GlobeNewsWire

Plus Therapeutics Announces Private Placement Financing of up to $18 Million

AUSTIN, Texas, May 06, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq:  PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced pl...

2 months ago - GlobeNewsWire

Plus Therapeutics Receives $3 Million Award Recommendation from the United States Department of Defense

Plus now has $23 million in active awards support for the Company's targeted radiotherapeutic pipeline Funding for pediatric brain cancer treatment is expected to begin in Q3 2024,  pending contract f...

3 months ago - GlobeNewsWire

Neuro-Oncologist Andrew Brenner, M.D., Ph.D. and Barbara Blouw, Ph.D.

The addition of both Dr. Brenner and Dr. Blouw substantially expands Plus internal expertise in key areas Dr. Brenner will maintain his academic commitments but will greatly contribute to Plus' scient...

3 months ago - GlobeNewsWire

Plus Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights

Began enrollment of the 5 th of an anticipated 7 planned dosing cohorts for the ReSPECT-LM Phase 1 dose escalation trial with rhenium ( 186 Re) obisbemeda for leptomeningeal metastases (LM)

4 months ago - GlobeNewsWire

Plus Updates Financial and Cash Guidance for 2024

Plus Receives $3.3M in grant revenue in Q4 2023 Forecasts additional $6.9M of grant revenue for 2024 Enters into debt restructuring deal with Pershing Capital to reduce 2024 cash burn by $3.7M AUSTIN,...

7 months ago - GlobeNewsWire

Plus Therapeutics to Host Virtual KOL Event on New Phase 2 ReSPECT-GBM Data in Recurrent Glioblastoma Presented at the Society for NeuroOncology (SNO) Conference on Monday, November 20, 2023

AUSTIN, Texas, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced pla...

8 months ago - GlobeNewsWire

Plus Therapeutics Granted U.S. FDA Orphan Drug Designation to Rhenium (186Re) Obisbemeda for the Treatment of Breast Cancer with Leptomeningeal Metastases

AUSTIN, Texas, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq:  PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced p...

9 months ago - GlobeNewsWire

Plus Therapeutics Announces Share Repurchase Program

AUSTIN, Texas, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced pla...

9 months ago - GlobeNewsWire

Plus Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights

New survival data from 15 patients in the Phase 2 ReSPECT-GBM trial of rhenium ( 186 Re) obisbemeda in recurrent glioblastoma (rGBM) will be presented at SNO Annual Meeting on November 17 th ; Company...

9 months ago - GlobeNewsWire

Plus Therapeutics to Present at the Society for NeuroOncology Annual Meeting and will Host Key Opinion Leader Webinar

Update on the ReSPECT-GBM Trial, including Phase 2, with Rhenium-186 Obisbemeda in Recurrent Glioblastoma will be Presented at SNO Annual Meeting Update on the ReSPECT-GBM Trial, including Phase 2, wi...

9 months ago - GlobeNewsWire

Plus Therapeutics to Announce Third Quarter 2023 Financial Results and Host Conference Call on October 31, 2023

AUSTIN, Texas, Oct. 23, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq:  PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced p...

9 months ago - GlobeNewsWire

Plus Therapeutics Completes Dosing in Cohort 4 of ReSPECT-LM Phase 1 Clinical Trial of Rhenium (¹⁸⁶Re) Obisbemeda in Leptomeningeal Metastases

Cohort 4 of the ReSPECT-LM Phase 1 dose escalation trial is the first of 4 planned cohorts in Part B; the Company anticipates moving into Cohort 5 following standard safety review

10 months ago - GlobeNewsWire

Plus Therapeutics to Participate in the Jones Trading Healthcare Summit and ThinkEquity Conference in October

AUSTIN, Texas, Oct. 09, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced pla...

10 months ago - GlobeNewsWire

Plus Therapeutics Receives $1.9 Million Advance Payment from CPRIT and Plans to Present at the CPRIT Innovations in Cancer Prevention and Research Conference

AUSTIN, Texas, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq:  PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced ...

11 months ago - GlobeNewsWire

Biocept Signs CNSide™ Licensing Agreement with Plus Therapeutics

SAN DIEGO--(BUSINESS WIRE)---- $BIOC #CSF--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products, and services, announces the signing of a non-exclusive licensing a...

11 months ago - Business Wire

Plus Therapeutics Enters into License Agreement for Cerebrospinal Fluid Tumor Cell Enumeration Assay

CNSide™ assay is the gold standard diagnostic cerebrospinal fluid (CSF) assay for patients with suspected central nervous system (CNS) cancers

11 months ago - GlobeNewsWire

Plus Therapeutics Initiates Part B of ReSPECT-LM Phase 1/2a Trial for Leptomeningeal Metastase

AUSTIN, Texas, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq:  PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced ...

11 months ago - GlobeNewsWire

Plus Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference

AUSTIN, Texas, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologi...

11 months ago - GlobeNewsWire